Vienna (ots/PRNewswire) - Croma-Pharma, a global player and challenger in the dynamically growing, minimally invasive aesthetics market, announces that it will launch Pliaglis®, a topical local anaesthetic for superficial dermatological procedures, in its European core markets including Germany, the United Kingdom ("UK"), and Ireland. Further markets including Brazil will follow by the end of 2023. The anaesthetic cream ...
Burghausen/Germany (ots) - The Medias Hospital has officially enrolled in the accreditation program of IASIOS to further ensure highest quality standards in Interventional Oncology as an important aspect of oncological patient care. The Medias Hospital has taken the next step to committing to the highest standards when it comes to interventional oncology (IO) care and ...
Lausanne, Switzerland (ots) - - Debiopharm combines its potent WEE1-inhibitor Debio 0123 with standard-of-care therapy to short-circuit DNA damage repair (DDR) in adults with recurrent or progressive small cell lung cancer (SCLC). - The first patient dosed at Vall d’Hebron Hospital (Barcelona, Spain), was ...
During the COVID-19 pandemic, an increase in the chronic autoimmune disease type 1 diabetes was observed in children, also in Germany. Researchers at Helmholtz Munich and TU Dresden, in cooperation with the Kassenärztliche Vereinigung Bayern (KVB), have now investigated whether there is a temporal association between infection with the SARS-CoV-2 virus and the ...
Aachen (ots) - - Knee osteoarthritis is a progressive condition affecting over 360 million people worldwide and may have severe symptoms, including pain. - Grünenthal is running a global Phase III programme to investigate the efficacy and safety of intra-articular injections of resiniferatoxin, a non-opioid ...
Lausanne (ots) - - Glioblastomas (GBM) are among the most aggressive and lethal tumors of the central nervous system with a 5-year survival rate of only 6.8%. - Debiopharm is combining its potent, brain penetrant WEE1 inhibitor Debio 0123 with standard of care (SOC) therapy. Debio 0123 hopes to hinder DNA damage ...
A new study conducted by Helmholtz Munich researchers reveals that ultrafine particles, representing the smallest size fraction of particulate air pollution, might be more dangerous to human health than larger particles. These findings add to the growing body of evidence that it may be insufficient to focus on larger particle concentrations and gases when assessing public health risks. It was now published in the ...
Vienna (ots/PRNewswire) - In the news release, Croma-Pharma reports 27% revenue growth in 2022 and targets further revenue growth in 2023 and thereafter, issued 09-May-2023 by Croma-Pharma over PR Newswire, we are advised by the company that the footnote [1] has been updated. The complete, corrected release follows: Croma-Pharma reports 27% revenue growth in 2022 and targets further revenue growth in 2023 and thereafter - ...
Fraunhofer-Institut für Produktionstechnologie IPT
Freiburg, Germany (ots) - Björn Cochlovius Ph.D. has become the new CEO of Eleva, a Freiburg-based biotech company and the developer of “Bryotechnology”, a unique and pioneering process for the moss-based production of complex therapeutic proteins. The renowned oncologist, immunologist, and molecular biologist ...
Barcelona, Spain, Düsseldorf, Germany and Paris (ots/PRNewswire) - Transaction enables Neuraxpharm to further focus on its core CNS therapeutic area and for Inke to accelerate its development as an independent entity Neuraxpharm Group ("Neuraxpharm"), the leading European specialty pharmaceutical company focused on ...
Aachen, Germany and London, England (ots) - - Dr Ramin Raouf from King's College London and Grünenthal strive to develop reliable microfluidic culture models relevant for pain research based on human induced pluripotent stem cell-derived neurons - Grünenthal has expertise in developing human induced pluripotent ...
Berlin (ots) - Berlin-based x-cardiac GmbH is pleased to announce that Freiburg University Hospital has become the second pilot customer for its AI-based software "x-c-bleeding" for predicting severe bleeding complications after cardiac surgery. With the implementation of "x-c-bleeding", the University Hospital ...
Austrian State Printing House (OSD)
LTS Lohmann Therapie-Systeme AG
Andernach, Germany (ots) - LTS LOHMANN Therapie-Systeme AG (“LTS”), a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches (“TTS”), Oral Thin Films (“OTF”) and Micro Array Patches (“MAP”) announces the signing of the ...
Technische Universität München
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE Electron microscopy: Nano-reporter proteins make invisible processes visible Genetically encoded nano-barcodes - New gene reporter system for electron microscopy - Uses barcodes to identify cellular states and structures that would otherwise remain unidentified - Important step to better elucidate cellular structural changes also in disease How do the nerve cells in our brain communicate with each other? What processes take place ...
Düsseldorf (ots) - - First-quarter revenues grew organically by 21.0% - Adjusted EBITDA up organically by 24.8% - Gerresheimer confirms guidance for financial year 2023 Gerresheimer AG, a leading provider of healthcare & beauty solutions and drug ...
Munich / London / Athens (ots) - - Adragos on a growth path: Three locations in Europe and five globally - Acquisition strengthens Adragos' end-to-end integrated pharmaceutical product development service offering - Agreement on further product development activities for Clinigen Munich-based pharmaceutical contract ...
STADA and Xbrane launch ranibizumab to support patient access in Europe - Ranibizumab biosimilar is being launched in major European markets - Ranibizumab is the first product brought to market through a strategic collaboration between STADA and Xbrane, marking Xbrane’s first commercial launch and ...
BOSTON, LAUSANNE & LJUBLJANA, Slovenia (ots) - Debiopharm Innovatoin Fund & Taiwania Capital co-lead financing round for Genialis to propel drug development, diagnostics and treatment planning through AI/ML-enabled platform with a biology-first approach Genialis, a computational precision medicine company unraveling complex biology to find new ways to address disease, ...
